Book chapter
Chapter 18 - Lenacapavir: a first-in-class HIV-1 capsid inhibitor for the treatment of multidrug-resistant HIV infections
Drug Discovery Stories, pp 341-349
2025
Abstract
Combination antiretroviral therapy (cART) has provided exceptional advancements in the management of HIV, significantly reducing morbidity and mortality. However, the onset of multidrug-resistant strains and the long-term toxicity of current medications underscore the urgent need for new antiretroviral drugs with novel mechanisms. The HIV-1 capsid (CA) protein is a prime therapeutic target owing to its pivotal role in the virus’s life cycle and its high degree of conservation across different HIV-1 strains. The interprotomer pocket between the N-terminal domain (NTD) and the C-terminal domain (CTD) within the CA protein serves as a crucial interaction site for host dependency factors, as well as for the innovative small-molecule modulator Lenacapavir (LEN). LEN, distinguished by its potent antiviral efficacy and long-acting nature, is the first drug approved to target the HIV-1 CA protein. This chapter provides an overview of the discovery of LEN, elucidates its mechanism of action, and discusses the clinical trials that led to its groundbreaking advent in antiretroviral drug development.
Metrics
17 Record Views
1 citations in Scopus
Details
- Title
- Chapter 18 - Lenacapavir: a first-in-class HIV-1 capsid inhibitor for the treatment of multidrug-resistant HIV infections
- Creators
- Dang Ding - University of JinanDazhou Shi - University of JinanShujing Xu - University of JinanYang Zhou - University of JinanXiangyi Jiang - University of JinanXinyong Liu - University of JinanAlexej Dick - Drexel UniversityPeng Zhan - University of Jinan
- Publication Details
- Drug Discovery Stories, pp 341-349
- Publisher
- Elsevier
- Resource Type
- Book chapter
- Language
- English
- Academic Unit
- Biochemistry and Molecular Biology
- Scopus ID
- 2-s2.0-85213168983
- Other Identifier
- 991021931315304721